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Abstract Epstein Barr virus (EBV) infects 95% of the global population and is associated with up to 2% of cancers globally.
Immunoglobulin G (IgG) antibody levels to EBV have been shown to be heritable and associated with developing malignan-
cies. We, therefore, performed a pilot genome-wide association analysis of anti-EBV IgG traits in an African population, using
a combined approach including array genotyping, whole-genome sequencing and imputation to a panel with African sequence
data. In 1562 Ugandans, we identify a variant in human leukocyte antigen (HLA)-DQA1, rs9272371 (p = 2.6 × 10−17) associated
with anti-EBV nuclear antigen-1 responses. Trans-ancestry meta-analysis and ﬁne-mapping with European-ancestry indivi-
duals suggest the presence of distinct HLA class II variants driving associations in Uganda. In addition, we identify four puta-
tive, novel, very rare African-speciﬁc loci with preliminary evidence for association with anti-viral capsid antigen IgG
responses which will require replication for validation. These ﬁndings reinforce the need for the expansion of such studies
in African populations with relevant datasets to capture genetic diversity.
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Introduction
Epstein Barr virus (EBV) is a common human herpesvirus
infecting 95% of the global adult population. Following pri-
mary infection, often in childhood, EBV establishes a latent
infection in B cells, allowing virus persistence in the face
of an active immune system. EBV can reactivate from latency
and enter the lytic cycle allowing viral replication and trans-
mission. The majority of people live with EBV infection with
the absence of clinical symptoms. However, EBV causes the
self-limiting condition, Infectious Mononucleosis and up to
2% of cancers, including Burkitt’s lymphoma, Hodgkin’s
lymphoma, nasopharyngeal carcinoma and some gastric can-
cers [1, 2]. It is also thought to be a risk factor for the
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development of autoimmune diseases such as systemic
lupus erythematosus, rheumatoid arthritis and multiple
sclerosis [3, 4].
EBV infection induces a strong cell-mediated and humoral
immune response which actively contains EBV replication in
healthy individuals. Antibodies against EBV nuclear antigen-1
(EBNA-1) reﬂect infection history, whilst those against viral
capsid antigen (VCA) reﬂect viral reactivation and together
are widely used as markers to study the latent and lytic
stages of infection, respectively. Early life infection and
high antibody titres have been strongly linked to the devel-
opment of certain cancers [2, 5–7]. In a single individual,
antibody titres have been found to remain fairly constant
throughout life in the absence of immunosuppression or
intense stress [6]. In addition, inter-individual variability in
IgG responses to EBNA-1 and VCA has been found to be
a 32–48% heritable trait [8–10] and thus is suggestive of
host genetic inﬂuence.
While EBV has been extensively studied, the host genetics
underpinning potential disease outcome are still unclear
[11], particularly in Africa. Recent genetic association stud-
ies in Mexican American, and European ancestry population
cohorts have reported variants in the human leucocyte anti-
gen (HLA) class II region of the major histocompatibility
complex on chromosome 6p21.3, contributing to variability
in responses to EBNA-1 [9, 12]. No genome-wide associ-
ation studies (GWASs) have been done for anti-VCA IgG
responses. With less than 5% of GWASs conducted in
African populations [13, 14], the contribution of human gen-
etic variation to disease traits in such diverse populations
remains largely uncharacterized. We aim to bridge the gap
in understanding host genetic factors that contribute to
EBV immune response serological traits in an African popu-
lation cohort.
Here, we present a pilot study describing the ﬁrst genome-
wide association analysis performed for anti-EBV IgG traits in
an African population. We highlight the combination of whole-
genome sequencing and imputing genotypes to a panel with
additional African sequence data to aid discovery of low-
frequency and population-speciﬁc variants. We replicate var-
iants in the HLA class II region contributing to anti-EBNA
IgG response levels and also perform trans-ethnic meta-
analysis and ﬁne-mapping of EBNA-1 IgG traits with an add-
itional cohort of European ancestry, revealing distinct variants
driving associations in the two populations. Finally, we identify
four potentially novel, rare loci that are African-speciﬁc with
preliminary evidence of association with anti-VCA IgG seros-
tatus, warranting replication in larger sample sizes.
Methods
Samples and ethics
The general population cohort (GPC) is a community-based
open cohort study originally established in 1989, by the UK
Medical Research Council and the Uganda Virus Research
Institute, in the Kalungu District, south-western Uganda,
to examine prevalence, incidence, risk factors and trends
of infection with the human immunodeﬁciency virus (HIV)
in a rural African population [15]. Data are collected
through an annual census, health questionnaire and include
blood specimens for the serological survey, details of sexual
behaviour, medical, socio-demographic and geographic fac-
tors. As part of a larger investigation of oncogenic infections
in the GPC, we measured antibodies against EBV from a
cross-sectional sample of people at three-time points
between 1990 and 2008. The sample was age and sex-
stratiﬁed to provide a 1:1 sex ratio and to increase the pro-
portion of participants >15 years old. Of the original ∼9000
people tested, we were able to link EBV phenotype results
from 1570 people (Mean age ± S.D. = 34 ± 19.6 years, 54%
female) to the genetic data generated from samples col-
lected from the GPC in 2011. Informed consent was
obtained for genetic testing from participants either with a
signature or a thumbprint if the individual was unable to
write. The study was approved by the Uganda Virus
Research Institutes, Research Ethics committee (UVRI-
REC) (Ref. GC/127/10/10/25), the Uganda National
Council for Science and Technology (UNCST), and the
UK National Research Ethics Service, Research Ethics
Committee (UK NRES REC) (Ref. 11/H0305/5).
Serology
We quantiﬁed mean ﬂuorescence Intensities (MFI) of IgG
antibodies to EBNA-1 and VCA using multiplex serology
on the Luminex platform based on glutathione-S-transferase
(GST) fusion capture immunosorbent assays combined with
ﬂuorescent bead technology [16]. In this study, 94% of indi-
viduals were categorized as seropositive based on detectable
IgG MFI >519 and/or >165 cutoffs for EBNA-1 and VCA,
respectively.
Genotyping, imputation and whole genome
sequencing
5000 GPC samples were densely genotyped on the Illumina
HumanOmni 2.5 M BeadChip array and we then imputed
additional variants into the genotype chip dataset using a
merged 1000 Genomes phase 3 [17], African genome vari-
ation project [18] and UG2G (Uganda 2000 Genomes)
(Gurdasani et al. in submission) reference panel in
IMPUTE2 [19]. Whole genome sequencing was performed
on 2000 samples with 100 base paired-end sequencing at
4× coverage on the Illumina HiSeq 2000 platform following
the manufacturer’s protocol (Gurdasani et al. in submission).
Quality control
Stringent variant and sample quality control (QC) ﬁltering
were performed. Low-quality variants that mapped to
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multiple regions within the human genome or did not map
to any region, and duplicate variants genotyped on the
chip were removed. We excluded samples with a call rate
<97% and heterozygosity >3 S.D. from the mean, discordant
genetic sex and reported sex, and sites deviating from Hardy
Weinberg equilibrium (p < 10−8). Following imputation,
we only included high-quality sites (info score >0.3 and
r2 > 0.6) with minor allele frequency (MAF) ⩾0.5%. We
also removed samples without matching phenotype and
genotype or sequence data. Of the merged datasets, 343
samples had overlapping genotype and sequence variant
calls for which a ﬁnal concordance of 93.1% was achieved
for all SNPs. The merged datasets post QC ﬁltering resulted
in 1562 samples with EBV phenotypes and ∼17 M SNPs
across the autosomes and X-chromosome for analyses.
Principal components analysis (PCA)
PCA was performed using SMARTPCA in Eigensoft v4.2
with 1000 Genomes Project phase 3 and African Genome
Variation Project populations as a reference panel. PCA
was done including markers with MAF ⩾0.05 after linkage
disequilibrium (LD) pruning (r2 = 0.5) using a sliding window
approach with a window size of 200 Kb, sliding 5 SNPs
sequentially.
Heritability analyses
Narrow-sense heritability (h2) for anti-EBNA-1 IgG and
anti-VCA IgG traits were estimated using a linear mixed
model (LMM) in FaST-LMM with two random effects, one
based on genetic effects and the other on environmental
effects using spatial location [20] recorded as global position
system (GPS) coordinates as a proxy for environmental
effects.
Association analyses
We conducted analyses for both quantitative antibody traits
and discrete serostatus (i.e. presence/absence of antibody
response) based on MFI cutoffs applying a linear or logistic
regression model, respectively, in R. For anti-EBNA-1 IgG
analysis age, sampling round, Hepatitis B virus and
Hepatitis C virus status were adjusted for as signiﬁcant cov-
ariates (online Supplementary Table S1). For anti-VCA IgG
analysis Kaposi’s sarcoma-associated virus and HIV statuses
were also adjusted for in addition as signiﬁcant covariates
(online Supplementary Table S1). Residuals of MFI values
used for analyses were transformed using inverse, rank-
based normalization in R to ensure a standard normal distri-
bution for the phenotypes and ascertained by visualization
and Shapiro–Wilk test in R (online Supplementary Fig. S1).
To control for cryptic relatedness and population structure
within the GPC, the GWAS was performed using the stand-
ard mixed model approach in genome-wide efﬁcient mixed-
model association (GEMMA) [21]. A kinship matrix to
deﬁne pairwise genetic relatedness among individuals was
generated using pooled imputed genotypes and sequence
data for all autosomes and X-chromosome using the k = 1
option in GEMMA. The data were LD pruned (r2 = 0.2)
using dosages and a MAF threshold of 1% was applied.
Genotyping or sequencing method was also adjusted for
as additional covariates during analysis in GEMMA. To iden-
tify distinct SNPs, conditional analysis was performed
in GEMMA. Each SNP within 1 MB of the lead association
SNP was conditioned. If any SNP was statistically signiﬁcant
it was added stepwise onto the mixed model and analysed
jointly, this was done until no SNPs with p < 5 × 10−9
remained. All SNPs remaining statistically signiﬁcant were
considered distinct association signals. For conditional ana-
lysis where genotype data was unavailable, association sum-
mary statistics were obtained and conditional analysis as
described above was performed using genome-wide com-
plex trait analysis (GCTA).
Functional annotation of candidate variants
To functionally annotate our most signiﬁcant associations
we used the Ensembl Variant Effect Predictor (VEP) and
the gene/tissue expression database (GTEx) to access data
on expression quantitative trait loci (eQTLs) from tissues.
Trans-ethnic meta-analysis and ﬁne mapping
MANTRA was used to perform a genome-wide trans-ethnic
meta-analysis for anti-EBNA IgG responses with association
summary statistics of 1473 EBV seropositive individuals from
our Ugandan GWAS combined with publically available data
of 1000 Genomes imputed European ancestry GWAS from
2162 seropositive individuals, giving a total of 3635 indivi-
duals with ∼4.6 million shared SNPs for analysis. The
MANTRA approach leverages differences in LD structures
across populations to account for differences in genetic
architecture and accommodates heterogeneity of allelic
effects between distantly related populations within a
Bayesian partition framework [22]. To determine statistical
signiﬁcance, we used a threshold of log10 Bayes Factor
(BF) >6, which is comparable with a p < 5 × 10−8, previously
determined by Wang et al. [23]. Heterogeneity of allelic
effect sizes was calculated using Cochran’s Q-test for het-
erogeneity in METAL [24]. Using MANTRA results we gen-
erated 99% credible sets most likely to drive association
signals and contain causal variants (or tagging unobserved
causal variants) and compared ﬁne-mapping intervals for
each associated lead SNP by analysing the variants 500 kb
up and downstream of the lead SNP in the Ugandan and
combined Ugandan + European datasets. For this, posterior
probabilities were calculated for SNPs and then ranked in
decreasing order according to BF, proceeding down the
rank until the cumulative posterior probability exceeded
99% as described previously [25, 26]. All SNPs ⩾0.99
were included in the credible sets.
cambridge.org/gheg
Results
Assessing the genetic contribution to anti-EBV
IgG response traits in a rural African cohort
To assess the contribution of human genetic variation on
antibody responses to EBV we investigated 1570 individuals
from a rural GPC [15] in south-western Uganda, and per-
formed a GWAS combining whole-genome sequencing
and dense genotyping data with imputation to a merged
1000 Genomes phase 3, African genome variation project
(AGVP) [18] and UG2 G (Uganda 2000 Genomes)
(Gurdasani et al. in submission) reference panel. In this
cohort, 94% (1473/1570) of individuals were categorized
as EBV seropositive (i.e. presence of detectable IgG
response to EBNA-1 or VCA) based on mean ﬂuorescence
intensity (MFI) cutoffs [16]. Stringent sample and variant QC
left 1562 individuals with EBV anti-EBNA-1 and anti-VCA
IgG phenotypes and ∼17 M SNPs across autosomal markers
and X-Chromosome for analyses as detailed in the methods
section. Homogeneity in the study population was ascer-
tained by PCA using Eigensoft v4.2 [27] with AGVP popula-
tions as a reference panel (online Supplementary Fig. S2).
As previous studies have reported heritability of IgG
responses to EBNA-1 at 37–43% and to VCA at 32–48%
[8–10], we also explored the heritability of anti-EBV IgG
serological traits in the GPC. In this study, our estimates
of heritability for anti-EBNA-1 and anti-VCA IgG responses
were 21.5% and 9.8%, respectively, suggesting a heritable
component albeit lower. After correction for a shared
environment, accounted for by GPS coordinates [20], our
estimates were further reduced to 12% and 7.6%, respect-
ively. To further investigate the genetic determinants of
response to EBV infection in this population we conducted
GWAS for each continuous antibody trait and discrete ser-
ostatus using a linear mixed model and kinship estimation in
GEMMA [21]. This model accounted well for population
structure and cryptic relatedness as shown by genomic inﬂa-
tion factor (λ) ∼1.0 for all traits (online Supplementary
Fig. S3). Correcting for multiple testing and accounting
for the lower LD in African populations the genome-wide
signiﬁcance threshold was adjusted to p < 5 × 10−9
(Gurdasani et al. manuscript in submission).
Genetic determinants of anti-EBNA-1 IgG
response
Consistent with previous ﬁndings, we identiﬁed signiﬁcant
associations for anti-EBNA-1 IgG antibody responses in
the HLA class II region (Fig. 1 and online Supplementary
Fig. S3). The C-allele at our lead SNP rs9272371 in HLA-
DQA1 (p = 2.6 × 10−17, β =−0.36) was associated with
lower antibody response levels (Table 1), suggesting
improved viral control and thus a protective effect on
potential predisposition to disease. The same SNP in a
European ancestry GWAS showed no evidence of signiﬁcant
association (p = 0.139) [12] (online Supplementary Table S2)
and was absent in a Mexican American study [9]; as this may
be owing to allelic heterogeneity or differences in LD struc-
ture in these populations, further investigation is needed to
reﬁne this signal (see below). The expression of 10 genes
(C4A, HLA-DQA1, HLA-DQB1-AS1, HLA-DQB1, HLA-DQB2,
HLA-DRB1, HLA-DRB5, XXbac-BPG254F23.6, NOTCH4, HLA-
DMA) in 34 tissues were found to be affected by
rs9272371 in the GTEx database. All of these genes are
known to mediate immune function. rs9272371-C was sig-
niﬁcantly associated with a downregulation of expression
of HLA-DQA1 in all tissues including whole blood (eQTL p
= 5.2 × 10−36, β =−0.75) and EBV transformed lymphocytes
(eQTL p = 9 × 10−12, β =−0.94), which is consistent with
the direction of our associations (Table 1).
Trans-ethnic meta-analysis and ﬁne mapping of
anti-EBNA-1 IgG response
Next, we used MANTRA [22] to perform a genome-wide
trans-ethnic meta-analysis for anti-EBNA IgG responses,
with association summary statistics of 1473 EBV seroposi-
tive individuals from our Ugandan GWAS combined with
2162 seropositive individuals from the 1000 Genomes-
imputed European ancestry GWAS [12], giving a total of
3635 individuals with ∼4.9 million shared SNPs for analysis.
We excluded genotype data from the Mexican American
GWAS as the SNP density was not comparable. Using a
threshold of log10 BF >6 [23] we found strong evidence of
association in the HLA class II region with lead SNP
rs6927022 (log10BF = 31.8) previously identiﬁed as the
lead association SNP in the European ancestry study, whilst
our Ugandan lead SNP rs9272371 (log10BF = 15.8) displayed
heterogeneity in effect sizes in the two studies (PQ = 3.56 ×
10−8) (Fig. 2, Table 2). rs6927022 is similarly associated with
the expression of nine out of the 10 genes affected by
rs9272371. While rs6927022 was signiﬁcant in our study
(p = 2.01 × 10−9) and in moderate LD with our lead SNP
rs9272371 (r2 = 0.32) (online Supplementary Fig S4), the
association was markedly attenuated when conditioned
on rs9272371 (pcond = 0.0065) (online Supplementary
Table S2). To further investigate whether the signals are dis-
tinct or partially tagging an un-typed functional variant con-
tributing to both underlying association signals, we
performed reciprocal conditional analysis of rs6927022 on
our Uganda GWAS in GEMMA and also conditioned on
our lead SNP rs9272371 in the European GWAS with asso-
ciation summary statistics using GCTA [28]. Both lead SNPs
remained genome-wide signiﬁcant in the respective cohorts
after adjusting for the effect of the other (online
Supplementary Table S2). Together, these ﬁndings suggest
rs9272371 and rs6927022 are likely to be distinct variants
in the HLA class II region, with a single signal in Europeans
(rs6927022) and a signal mostly driven by rs9272371 in
Uganda (online Supplementary Table S2). No other locus
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was found to be in association with anti-EBNA-1 IgG
response.
The availability of whole-genome sequence data and smal-
ler LD blocks in African populations are advantageous for the
reﬁnement of genetic association signals. In line with this,
using MANTRA results we generated 99% credible sets
most likely to drive association signals and contain causal var-
iants (or tagging unobserved causal variants) and compared
ﬁne mapping intervals for each associated lead SNP by analys-
ing the variants 500 kb up and downstream of the lead SNP
in the Ugandan and combined Ugandan + European datasets
as described previously [25, 26]. This resulted in only one
SNP in each credible set, rs6927022 for the Ugandan +
European, and rs9272371 for the Ugandan GWAS respect-
ively, further suggesting that rs6927022 does not fully drive
associations in the Ugandan population.
Table 1. Summary of genome-wide signiﬁcant association results in the GPC
Trait Chr:Pos (b37) SNP Gene Consequence EA EAF (%) p, βSNP/OR (95% CI)
EBNA-1 QT 6:32604654 rs9272371 HLA-DQA1 Intronic C 30.5 2.6 × 10−17, −0.36 (−0.26 to −0.42)
EBNA-1 Serostatus 6:32604654 rs9272371 HLA-DQA1 Intronic C 30.5 3.5 × 10−10, 0.89 (0.86–0.93)
VCA Serostatus 2:43590060 rs183816209 THADA Intronic T 0.5 4.5 × 10−9, 0.59 (0.41–0.77)
VCA Serostatus 7:10280129 rs190139255 – Intergenic G 0.5 1.0 × 10−9, 0.57 (0.39–0.76)
VCA Serostatus 14:88403492 rs115256851 GALC Intronic C 1.1 6.9 × 10−10, 0.69 (0.57–0.81)
VCA Serostatus 17:64836303 rs114676416 CACNG5 Intronic G 8.1 2.2 × 10−9, 0.86 (0.82–0.91)
EBV Multitrait 6:32604654 rs9272371 HLA-DQA1 Intronic C 30.5 5.8 × 10−21, −0.36 (−0.27 to −0.44)
EA, effect allele; EAF, effect allele frequency; QT, quantitative trait.
Fig. 1. Regional association plot for anti-EBNA-1 IgG response levels in 1473 individuals. (Genome-Wide signiﬁcance threshold = p < 5
× 10−9). The lead SNP rs9272371 (p = 2.6 × 10−17) located in an intron in HLA-DRB1 on chromosome 6 is labelled and coloured in
purple. LD (r2) was calculated based on the Ugandan SNP genotypes used in this study.
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Genetic determinants of anti-VCA IgG serostatus
For anti-VCA IgG response, 1344 individuals were categor-
ized as seropositive and 218 individuals as seronegative
based on VCA MFI cutoffs [16]. Using a case-control analysis
for discrete serostatus (i.e. seropositive v. seronegative), we
identiﬁed four potentially novel genome-wide signiﬁcant
associations (Fig. 3 and online Supplementary Fig. S5A).
rs183816209-T (p = 4.5 × 10−9, OR = 0.59, MAF = 0.5%) an
intronic variant in THADA on chromosome 2p21 (Fig. 3a),
rs190139255-G (p = 4.0 × 10−10, OR = 0.57, MAF = 0.5%)
an intergenic variant on chromosome 7p21.3 with the near-
est gene a non-coding RNA U3, 17 kb upstream (Fig. 3b),
rs115256851-C (p = 6.8 × 10−10, OR = 0.69, MAF = 1.1%)
an intronic variant in GALC on chromosome 14q31.3
(Fig. 3c) and rs114576416-G (p = 2.2 × 10−9, OR = 0.86,
MAF = 8.1%) an intronic variant in CACGN5 on chromosome
17q24.2 (Fig. 3d). All lead SNPs passed variant ﬁltering QC
post imputation and non-reference alleles were concordant
in individuals (N = 343) with overlapping genotype and
sequence data, giving conﬁdence in the accuracy of geno-
types (online Supplementary Table S3). All SNPs were asso-
ciated with seronegativity to VCA, potentially reﬂecting a
lack of EBV lytic replication, and were low-frequency var-
iants (Table 1). rs183816209 and rs115256851 were mono-
morphic in other 1000 Genomes phase 3 populations
besides African ancestry, suggesting that they are African-
speciﬁc. rs114676416 was also monomorphic in all popula-
tions except Africans and had MAF <1% in admixed
Americans. rs190139255 had no allele frequency data
reported in 1000 Genomes populations. No eQTL data
were available for these SNPs in the gene/tissue expression
database (GTEx) database. Quantitative analyses of anti-
VCA IgG levels did not yield any genome-wide signiﬁcant
associations (online Supplementary Fig. S5B). A multivariate
analysis combining anti-EBNA-1 and anti-VCA IgG
phenotypes (r2 = 0.3) did not yield any additional genome-
wide signiﬁcant results (online Supplementary Fig. S6). No
secondary associations were identiﬁed following conditional
analyses on the lead SNPs for all traits.
Discussion
In this study, we assessed the host genetic contribution on
anti-EBV IgG responses in a rural African population cohort
and highlight the utility of dense genotyping combined with
whole-genome sequencing and imputation of genotypes to a
combined reference panel with African sequence data to aid
locus discovery and reﬁnement of causal variants. As we are
limited by sample size, particularly in African populations, to
conduct well-powered GWASs for EBV-associated diseases
such as Burkitt’s Lymphoma, IgG response traits provide a
good intermediate phenotype, indicating the strength of
the humoral immune response and control of infection.
EBV infection is nearly ubiquitous in Africa, with infection
occurring early in childhood [7, 29, 30] and thus seronega-
tivity based on cutoffs, which are arbitrarily determined
Fig. 2. Trans-ethnic meta-analysis association plot for EBNA-1 IgG response levels in 3635 individuals of Ugandan and European
Ancestry (EUR). Grey dashed line: threshold = log10 BF > 6. The lead SNPs for EUR (rs6927022) and Uganda (rs9272371) GWASs on
chromosome 6 within the HLA region are labelled and circled in purple. Yellow: SNPs that meet the statistical signiﬁcance threshold.
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most likely reﬂect a low-level immune response as opposed
to lack of exposure to EBV. Previous studies have shown a
correlation of IgG levels both with Burkitt’s and Hodgkin’s
Lymphomas [5, 6, 31, 32], potentially predictive of disease
risk.
It is interesting that despite the fact that both anti-EBV
IgG traits display low heritability in this population after
accounting for a shared environment, we still identify strong
associations with SNPs contributing to variability in immune
responses in African populations. This suggests that while
genetic factors play a role in inter-individual variability in
immune responses, environmental effects may have not
been well accounted for by other studies, or differences in
gene–environment interactions between populations result
in different estimates. It is also a possibility that differences
in assay/study design could contribute to differences in her-
itability estimates, however, in this setting, exposure to
other pathogens are potentially strong cofactors inﬂuencing
these traits and thus have been adjusted for in the study.
We successfully replicated association signals for anti-
EBNA-1 IgG responses identiﬁed in individuals of Mexican
American and European descent, and through trans-ethnic
meta-analysis of European and African individuals in addition
to ﬁne-mapping identify distinct association signals in the
HLA class II region. As a result of the complex LD structure
in the HLA region, it is possible that both SNPs are tagging
an underlying HLA allele, which we would have to explore
further. Disentangling signals in the HLA region to pinpoint
causal alleles is nontrivial owing to the poor representation
of African ancestry data on HLA imputation reference
panels that are heavily skewed towards European popula-
tions. In the European GWAS, Hammer and colleagues
were able to achieve resolution of 4 digit classical HLA
alleles and amino acids in HLA-DRB1 through imputation
using the Type 1 diabetes genetics consortium (T1DGC)
Immunochip/HLA reference panel, which is predominantly
European [12, 33]. HLA class II molecules present peptides
to CD4+ T cells (T helper cells) eliciting both cell-mediated
and antibody responses to control viral infection. EBV has
also been found to use HLA class II molecules as a co-factor
mediating entry into B cell lymphocytes [34, 35]. Given HLA
haplotypes are highly polymorphic and display geographic
variability, conducting host genetic studies in diverse popula-
tions will allow us to capture variation and understand its’
contribution to EBV immune control and disease.
Previously, no GWASs had been done for anti-VCA IgG
responses and one linkage analysis had been performed
without success in identifying statistically signiﬁcant associa-
tions. For the ﬁrst time, we have identiﬁed putative novel,
African-speciﬁc genetic loci with evidence of association
with anti-VCA IgG serostatus (Table 1). While two of the
association signals, rs115256851 and rs114576416 appear
more robust with MAFs >1% and multiple SNPs in the
region highlighting evidence of association, the other two
SNPs rs183816209 and rs190139255 show weaker evidenceTa
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of association, with MAF ∼0.5% and minimal or no SNPs in
the region despite a high density of SNPs typed. Therefore,
taking into account that the SNPs are rare, replication in lar-
ger sample sizes will be essential to validate these ﬁndings
particularly as the majority (>90%) of individuals are infected
with EBV (i.e. Cases) and thus the number of controls is
relatively small.
In summary, the results of our pilot study substantiate the
contribution of host genetic variation to EBV immune
response and viral control. Our study reinforces the import-
ance of studying diverse populations to uncover population-
speciﬁc variants, differences in effect sizes and gene–envir-
onment interactions, which are known to vary signiﬁcantly
between European and non-European populations. A limita-
tion at this stage is that with a small sample size we are
underpowered to reliably identify rare genetic variants.
Expanding these studies in African populations to include
replication of the putative novel loci in larger sample sizes
is key to validating our ﬁndings. In addition, the development
of African resources such as an HLA imputation reference
panel based on African genetic data and gene expression
data will be crucial to be able to leverage approaches such
as GWAS and reﬁne our ﬁndings. While GWAS still remains
a leading tool to identify variants, to follow up signiﬁcant
ﬁndings and gain biological insights, the development of
pathway analysis tools with African populations also well
represented would be necessary to reliably identify gene
enrichments in pathways and protein interaction networks.
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